20
Participants
Start Date
April 12, 2024
Primary Completion Date
April 20, 2026
Study Completion Date
February 28, 2027
PD-1 and CRT
Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.
RECRUITING
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou
Sixth Affiliated Hospital, Sun Yat-sen University
OTHER